Top Markets
#1 Tornado Cash Tornado Cash +6.24%
#2 Story Story +4.55%
#3 UnifAI Network UnifAI Network +4.47%
#4 TENDIES TENDIES +3.72%
#5 Dual Dual +2.92%
#6 Seeker Seeker +2.82%
#7 Cash Cat Cash Cat +2.58%
#8 Figure Heloc Figure Heloc +2.55%
#9 HOME HOME +2.38%
#10 Orochi Network Orochi Network +2.35%
Coin of the day
Tornado Cash Tornado Cash
Ustawienia
Język
POLSKI
Waluta
USD
Motyw
Myriad Genetics, Inc. Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN
Pozycja w akcjach #16435
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company,... Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Cena akcji
$3.12
Ostatnia synchronizacja: 2026-09-01
Kapitalizacja rynkowa
$294.21M
Zmiana (1 dzień)
-3.26%
Zmiana (1 rok)
-54.86%
Kraj
US
Handel Myriad Genetics, Inc. (MYGN)

Kategoria

Healthcare
Historia dywidend dla Myriad Genetics, Inc. (MYGN)
Myriad Genetics, Inc. (symbol giełdowy: MYGN) wypłaciła łącznie 0 dywidend.
Suma wszystkich dywidend (skorygowana o podziały akcji): 0.00
Wskaźnik dywidendy (TTM): 0
Wypłaty dywidend dla Myriad Genetics, Inc. (MYGN) od 2026 do 2026
Roczne wypłaty dywidend
Rok Dywidenda (skorygowana o podziały akcji) Zmień
Za mało danych dla podanych dat.
Lista wszystkich wypłat dywidend
Rok Dywidenda Zmień
Za mało danych dla podanych dat.
Wypłaty dywidend firm podobnych lub konkurencyjnych
Firma Liczba wypłat dywidend Kraj
Thermo Fisher Scientific Inc. Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
TMO.US
60.00%
US
Danaher Corporation Danaher Corporation
Danaher Corporation
DHR.US
134.00%
US
WuXi AppTec Co., Ltd. WuXi AppTec Co., Ltd.
WuXi AppTec Co., Ltd.
603259.SS
0.00%
CN
Natera, Inc. Natera, Inc.
Natera, Inc.
NTRA.US
0.00%
US
IDEXX Laboratories, Inc. IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
IDXX.US
0.00%
US